Literature DB >> 12086885

Perspectives on the development of a molecularly targeted agent.

Brian J Druker1.   

Abstract

STI571 (Gleevec, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose and patient selection, as are possible mechanisms of resistance to STI571. Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm to other malignancies is explored.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12086885     DOI： 10.1016/s1535-6108(02)00025-9

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  42 in total

Review 1.  Molecular rearrangements and morphology in thyroid cancer.

Authors:  Todd G Kroll
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

2.  Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug.

Authors:  Yuan Liu; Krishna Mohan Bajjuri; Cheng Liu; Subhash C Sinha
Journal:  Mol Pharm       Date:  2011-11-22       Impact factor: 4.939

Review 3.  Designing clinical trials for brain tumors: the next generation.

Authors:  Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2007-01       Impact factor: 5.075

Review 4.  Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies.

Authors:  Trang H Au; Kai Wang; David Stenehjem; Ignacio Garrido-Laguna
Journal:  J Gastrointest Oncol       Date:  2017-06

5.  Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells.

Authors:  Rathi N Pillai; Lisa S Chen; Mary L Ayres; Billie J Nowak; Michael W Thomas; Elizabeth J Shpall; Michael J Keating; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2012-04-23

6.  Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.

Authors:  Nidhi Jyotsana; Amit Sharma; Anuhar Chaturvedi; Ramachandramouli Budida; Michaela Scherr; Florian Kuchenbauer; Robert Lindner; Fatih Noyan; Kurt-Wolfram Sühs; Martin Stangel; Denis Grote-Koska; Korbinian Brand; Hans-Peter Vornlocher; Matthias Eder; Felicitas Thol; Arnold Ganser; R Keith Humphries; Euan Ramsay; Pieter Cullis; Michael Heuser
Journal:  Ann Hematol       Date:  2019-05-18       Impact factor: 3.673

Review 7.  Harnessing preclinical mouse models to inform human clinical cancer trials.

Authors:  David H Gutmann; Kim Hunter-Schaedle; Kevin M Shannon
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

Review 8.  Acute lymphoblastic leukaemia in elderly patients: biological characteristics and therapeutic approaches.

Authors:  Tadeusz Robak
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients.

Authors:  Tian-Li Wang; Luis A Diaz; Katharine Romans; Alberto Bardelli; Saurabh Saha; Gennaro Galizia; Michael Choti; Ross Donehower; Giovanni Parmigiani; Ie-Ming Shih; Christine Iacobuzio-Donahue; Kenneth W Kinzler; Bert Vogelstein; Christoph Lengauer; Victor E Velculescu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-17       Impact factor: 11.205

10.  The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics.

Authors:  Abel D Jarell; Donald Lawrence; Hensin Tsao
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.